These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4751256)

  • 1. Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia.
    Kline I; Gang M; Woodman RJ; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):299-304. PubMed ID: 4751256
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentially useful combinations of chemotherapy detected in mouse tumor systems.
    Kline I
    Cancer Chemother Rep 2; 1974 Mar; 4(1):33-43. PubMed ID: 4133187
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthesis and metabolic behavior of the suggested active species of isophosphamide having cytostatic activity.
    Takamizawa A; Matsumoto S; Iwata T; Tochino Y; Katagiri K
    J Med Chem; 1974 Nov; 17(11):1237-9. PubMed ID: 4416021
    [No Abstract]   [Full Text] [Related]  

  • 4. Phosphorohydrazines of 4-oxo-4H-1-benzopyran and 1-benzopyran-2,4-dione exhibit antitumor activity against L1210 leukemia.
    Nawrot-Modranka J; Ochocki J; Graczyk J
    Pharmazie; 2004 Sep; 59(9):731-2. PubMed ID: 15497762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological studies with alkylsulfonyloxyalkyl substituted and chloroethyl substituted oxazaphosphorine-2-oxides. 1. Communication: relationship between chemical structure and pharmacological action.
    Brock N; Kuhlmann J
    Arzneimittelforschung; 1974 Aug; 24(8):1139-49. PubMed ID: 4371234
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of reserpine (NSC-59272)-induced hypothermia on lifespan in mouse L1210 leukemia.
    Fondy TP; Karker KL; Calcagnino C; Emlich CA
    Cancer Chemother Rep; 1974; 58(3):317-24. PubMed ID: 4841715
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical pharmacology of isophosphamide.
    Creaven PJ; Allen LM; Alford DA; Cohen MH
    Clin Pharmacol Ther; 1974 Jul; 16(1):77-86. PubMed ID: 4602057
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

  • 10. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
    Lelieveld P; van Putten LM
    Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
    Avery TL; Roberts D
    Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial of isophosphamide (NSC-109724)--results and side effects.
    Bremner DN; McCormick JS; Thomson JW
    Cancer Chemother Rep; 1974; 58(6):889-93. PubMed ID: 4614898
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer.
    Ahmann DL; Bisel HF; Hahn RG
    Cancer Chemother Rep; 1974; 58(6):861-5. PubMed ID: 4615785
    [No Abstract]   [Full Text] [Related]  

  • 15. Delayed toxicity of 4'-demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) in mice.
    Avery TL; Roberts D; Price RA
    Cancer Chemother Rep; 1973 Apr; 57(2):165-73. PubMed ID: 4742496
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacological studies with alkylsulfonyloxyalkyl substituted and chloroethyl substituted oxazaphosphorine-2-oxides. 2. Pharmacological characterization of 2-alkylsulfonyl-oxyalkylamino-oxazaphosphorine-2-oxides including immunological reaction].
    Arzneimittelforschung; 1974 Aug; 24(8):1149-60. PubMed ID: 4371545
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral and parenteral activity of 2,2'-anhydro-1- -D-arabinofuranosyl-5-fluorocytosine against both intraperitoneally and intracerebrally inoculated mouse leukemia.
    Fox JJ; Falco EA; Wempen I; Pomeroy D; Dowling MD; Burchenal JH
    Cancer Res; 1972 Oct; 32(10):2269-72. PubMed ID: 4673145
    [No Abstract]   [Full Text] [Related]  

  • 18. Phosphorus-nitrogen compounds XIX: distribution of 32P and effect of an active oncolytic on intracerebral leukemia in rodents.
    Cates LA; Cramer MB
    J Pharm Sci; 1976 Mar; 65(3):439-40. PubMed ID: 1263100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of platinum(II) choline complex on murine leukemias L1210 and P388.
    Ochocki J; Glinka R; Cieśliński M; Góra-Tybor J; Potemski P
    Pharmazie; 1997 Jul; 52(7):567-9. PubMed ID: 9266598
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of "3-oxauracil" (2,3-dihydro-1,3-6H-oxazine-dione) in L1210 leukemia.
    Ujházy V; Reiner P; Farkas J; Skoda J
    Neoplasma; 1977; 24(3):259-61. PubMed ID: 895936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.